Dr. Reddy's Laboratories Limited research snapshot
RDY AI stock analysis currently reads Dr. Reddy's Laboratories as a diversified India-based pharmaceutical company with global generics, branded markets, consumer healthcare, APIs, and a longer-term biosimilar and innovation build. At the July 12, 2026 data cutoff, RDY last closed near $13.19 with a verified market capitalization near $10.98 billion. FY26 revenue rose about 3% to $3.58 billion while profit attributable to equity holders fell about 24% to $457 million after lower lenalidomide sales, margin compression, and one-off charges. This page uses scenarios, technical levels, and source-backed data for informational research, not investment advice.
Current price
$13.19
Market cap
$10.98 billion
AI score
58 / 100
Rating
Solid global generics franchise with a near-term earnings reset
Trend status
Short-term downtrend after a July 10 selloff, with price below the 50-day and near the 200-day average
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Dr. Reddy's sells generic medicines, branded generics, consumer healthcare, APIs, and selected specialty and biosimilar products across North America, India, Europe, Russia and CIS, and other emerging markets. | High |
| Moat | Scale manufacturing, regulatory filing skill, a broad product portfolio, India brand presence, and cost position support the moat, but pure generics still face price competition and limited product-level pricing power. | Medium |
| Management | Co-Chairman and MD G. V. Prasad, with Chairman Satish Reddy, is reallocating capital toward base-business resilience, biosimilars, consumer health, and portfolio pruning after several one-off impairments. | Medium-high |
| Financial trend | FY26 revenue was $3.58 billion, up 3.2% year over year. Profit attributable to equity holders was $457 million, down 24%, with gross margin at 52.8% versus 58.5% in FY25. | High |
| Valuation | At $13.19, audited inputs imply about 24.0x FY26 diluted ADR EPS of $0.55, about 2.7x book value, and a depressed free-cash-flow yield after acquisition-related payouts. | Medium-high |
| Technical trend | After the July 10 decline, RDY traded below the roughly $14.3 50-day average and near or below the roughly $13.8 200-day average, with the 52-week range near $12.19 to $15.67. | Medium |
| Risk level | Risks include U.S. generic price erosion, concentration after lenalidomide, FDA quality findings, pipeline and biosimilar delays, Russia and emerging-market exposure, currency, and integration of consumer-health assets. | High |
| AI confidence | The company data record is strong, but AI cannot convert product launches, pricing, or regulator outcomes into a dependable price prediction. | High data confidence |
| Investment certainty | Medium-low certainty. Franchise quality and net cash help, yet earnings quality just reset and the multiple still prices a clean recovery. | Medium-low |
RDY AI stock forecast
The RDY AI stock forecast uses scenario math around the $13.19 July 10 close and FY26 diluted ADR EPS of $0.55. The audited three-year framework produced a bullish area near $17, a base area near $10, and a bearish area near $6 before dividends. These are scenarios, not price targets.
$16 to $18
More likely if India branded, Europe consumer health, emerging markets, complex generics, and biosimilars restore earnings growth near 12% annually, U.S. base business stabilizes after the lenalidomide step-down, margins recover, and investors re-rate RDY toward a low-20s earnings multiple.
$9.50 to $11
More likely if EPS compounds only around 5% annually, generic price pressure continues, free cash flow stays modest after reinvestment, and the market applies a mid-teens multiple closer to diversified generics peers.
$5.50 to $7
More likely if U.S. generics keep declining, new launches underdeliver, biosimilar timelines slip, quality or regulatory issues recur, currency and Russia risk bite, earnings fall further, and the multiple compresses toward 12x.
RDY AI technical analysis
RDY AI technical analysis is cautious as of the July 12, 2026 cutoff. Market data sources put the July 10 close near $13.19 after a roughly 5% drop, with a 50-day average near $14.3 to $14.4, a 200-day average near $13.8, average volume near 2.6 million shares, and a 52-week range of about $12.19 to $15.67. These levels are snapshots, not forecasts.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $13.19 | July 10, 2026 closing price used for market-cap and valuation math. |
| Near support | $12.50 to $12.20 | The lower half of the recent range and the 52-week low near $12.19 form the first deeper support zone. |
| Near resistance | $13.80 to $14.00 | The 200-day average area is the first reclaim zone after the July 10 decline. |
| 50-day moving average | About $14.30 to $14.40 | Investing.com snapshot near the data cutoff. Price was below this short-term trend reference. |
| 200-day moving average | About $13.80 to $13.85 | Nearby long-term reference that shifted from support toward resistance after the selloff. |
| Momentum | Weak after the July 10 gap lower | A roughly 5% single-day decline and a move under key averages weakens the short-term trend until volume and closes improve. |
| Volume | About 2.6 to 3.3 million shares on recent sessions | Compare post-earnings and product-news sessions with the multi-million-share average because generics news can fade quickly. |
| Volatility | 52-week range $12.19 to $15.67 | The band shows that pricing, product, and regulatory headlines can move RDY even with a historically low beta. |
| Invalidation | Sustained close below $12.19 | A break of the 52-week low would confirm a broader downtrend rather than a one-day shakeout. |
RDY AI trading strategy
This RDY AI trading strategy is a rules-based research framework, not personal advice. It connects price levels with U.S. generics base sales, India and emerging-market branded growth, Europe consumer health, launch cadence, margin recovery, free cash flow, FDA updates, and portfolio-level risk limits.
Watch for RDY to reclaim and hold the $13.80 to $14.40 zone with improving volume while subsequent quarters show stabilizing North America base sales, better gross margin, and visible contribution from India, Europe NRT, and new launches.
A close back below $12.50, especially with weaker guidance language, more price erosion, or a negative FDA quality update, should weaken the setup.
If RDY pulls back toward $12.50 to $12.20 without a new structural break, compare the valuation with normalized earnings power after lenalidomide, net cash, and the durability of branded and biosimilar growth.
Do not treat a lower price as enough evidence of value if gross margin, free cash flow, launch traction, or quality metrics keep deteriorating.
Track North America generics ex-lenalidomide, India secondary growth versus IPM, Europe NRT integration, Russia and emerging markets, PSAI volumes, ANDA and biosimilar milestones, gross margin, EBITDA margin, free cash flow after acquisitions, net cash surplus, and FDA inspection outcomes.
Position sizing should account for pharmaceutical event risk and should not rely on AI or consensus forecasts as certainty.
Investment research summary
Customers pay Dr. Reddy's for affordable, regulated access to generic and branded medicines, APIs, consumer healthcare products, and selected specialty or biosimilar therapies across major developed and emerging markets.
The moat rests on manufacturing scale, regulatory know-how, a wide filing pipeline, India brand equity, cost competitiveness, and growing consumer-health distribution. It is narrower in commoditized U.S. oral solids than in complex generics, brands, and biosimilars.
The thesis fails if the company cannot replace high-margin U.S. product cash flows, price erosion accelerates, biosimilar or complex launches slip, quality findings restrict capacity, Russia or currency shocks persist, or acquisition spend fails to earn returns.
G. V. Prasad and Satish Reddy remain closely associated with the founding family. Capital allocation should be judged by margin recovery, disciplined M&A such as NRT, biosimilar execution, and whether portfolio pruning raises returns on capital.
Affordable medicines, biosimilars, and chronic-care demand are multi-year industry supports. Offsets include U.S. generic price pressure, tender competition in Europe, patent and litigation cycles, and rising regulatory scrutiny of manufacturing quality.
Around 24x depressed FY26 ADR EPS leaves limited margin of safety if growth stays mid-single digits. The net-cash balance sheet helps, but investors still need evidence that earnings power can re-accelerate without paying for a full recovery in advance.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| RDY quote reference | $13.19 close on July 10, 2026 | MarketWatch and Finviz market data | July 12, 2026 |
| Market capitalization verification | $10.98 billion calculated from $13.19 x 832.71 million shares, matching reported market cap within 0.03% | Pineify financial_rigor.py with Yahoo and Macrotrends shares | July 12, 2026 |
| FY26 revenue | $3.580 billion / ₹335.933 billion, up 3.2% year over year, cross-checked with Macrotrends | Dr. Reddy's FY26 results Exhibit 99.2 | July 12, 2026 |
| FY26 profit attributable to equity holders | $457 million / ₹42.850 billion, down 24% year over year; diluted ADR EPS $0.55 | Dr. Reddy's FY26 results Exhibit 99.2 | July 12, 2026 |
| FY26 margins and cash generation | Gross margin 52.8%, EBITDA margin 22.8%, free cash flow after acquisition payouts ₹16.9 billion, net cash surplus ₹32.7 billion | Dr. Reddy's FY26 results Exhibit 99.2 | July 12, 2026 |
| Segment mix highlights | Global Generics ₹299.0 billion; North America ₹113.7 billion down 22%; India ₹62.2 billion up 16%; Europe ₹55.5 billion up 55% including NRT | Dr. Reddy's FY26 results Exhibit 99.2 | July 12, 2026 |
| Balance sheet snapshot at March 31, 2026 | Cash and investments $1.05 billion, loans and borrowings $824 million, equity $4.055 billion, net debt to equity -0.09 | Dr. Reddy's FY26 results Exhibit 99.2 | July 12, 2026 |
| Valuation arithmetic | PE 23.98x on $0.55 EPS, PB about 2.71x on $4.87 book value per share, dividend yield about 0.64% on the ₹8 recommended equity dividend translated at the company convenience rate | Pineify financial_rigor.py verify-valuation | July 12, 2026 |
| Technical snapshot | 50-day average about $14.3 to $14.4, 200-day average about $13.8, 52-week range $12.19 to $15.67, recent average volume about 2.6 million shares | Investing.com and MarketWatch technical and range data | July 12, 2026 |
This RDY AI stock analysis is an informational research tool only. It is not investment advice, not a recommendation to buy or sell Dr. Reddy's Laboratories Limited, and not a promise of future returns. Forecasts are scenario-based estimates from available public data and can be wrong.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
